@FinanceYF5: In 2025, the revenue generated by the two largest GLP-1 drugs will be approximately twice the combined revenue of OpenA…

X AI KOLs Timeline News

Summary

2025年两大GLP-1药物的收入约为OpenAI与Anthropic合并收入的两倍,在AI备受关注的同时,GLP-1已悄然成长为规模更大的商业浪潮,其影响远超减重领域。

In 2025, the revenue generated by the two largest GLP-1 drugs will be approximately twice the combined revenue of OpenAI and Anthropic. While all attention is focused on AI, GLP-1 has quietly grown into a larger-scale commercial wave. And its impact goes far beyond weight loss.
Original Article

Similar Articles

@FinanceYF5: This conclusion might surprise the market: In fact, OpenAI's growth rate has already surpassed Anthropic's. Ramp data shows that the quarter-over-quarter growth for Q3 so far is 82% and 76%, respectively. Why? GPT-5.6 Sol is becoming the choice of more developers; Fable…

X AI KOLs Timeline

OpenAI's growth rate exceeds Anthropic's, with Q3 quarter-over-quarter growth at 82% and 76% respectively, mainly because GPT-5.6 Sol is more popular among developers, while Fable 5's adoption is below expectations due to cost and data issues.

@FinanceYF5: Tech Fund projects that annualized AI revenue in markets outside China will reach $414 billion by the end of this year. Breakdown: 1. Anthropic and OpenAI: $187 billion Including both labs' own revenue and revenue earned by cloud providers from reselling their models. 2. Me…

X AI KOLs Timeline

Tech Fund projects that annualized AI revenue in markets outside China will reach $414 billion by the end of this year, with Anthropic and OpenAI combined accounting for $187 billion. It also estimates an overall IRR of roughly 12% on the $931 billion in AI capex spent over the past 3.5 years.